BioSpace News Archive

Business

AstraZeneca Expands ADC Portfolio with $600M Deal with LaNova

The company’s second antibody-drug conjugate deal of 2023, with Shanghai-based LaNova Medicines, adds a potential first-in-class GPRC5D-directed ADC for multiple myeloma.

May 15, 2023
·
2 min read
·
Kate Goodwin
Drug Development

Lilly-Backed Nido Biosciences Launches with $109M to Target Neurological Diseases

The precision neuroscience startup has notched $109 million in seed, Series A and B financing as it looks to further develop a Phase I candidate to treat a rare X-linked neuromuscular disorder.

May 15, 2023
·
1 min read
·
Lisa Munger
Drug Development

ReCode–a New Contestant in the mRNA Race

ReCode plans to use its SORT LNP genetic medicines delivery technology to treat CF and PCD patients who don’t respond to current treatments.

May 15, 2023
·
3 min read
·
Rosemary Scott
Drug Development

Astellas Wins FDA Approval for Hot Flash Treatment in Menopausal Women

Veozah, an oral once-daily medication, is the first FDA-approved NK3 receptor antagonist for hot flashes, a common symptom of menopause that can affect health and quality of life.

May 15, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program

Numab Therapeutics AG announced that the first subject has been dosed in the Phase 1 clinical study of NM26-2198, a first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis.

May 15, 2023
·
5 min read
Policy

FDA Grants SiSaf’s Innovative siRNA Therapy SIS-101-ADO Orphan Drug Designation and Rare Pediatric Disease Designation for the Treatment of Autosomal Dominant Osteopetrosis

SiSaf Ltd, an RNA delivery and therapeutics company, announces that SIS-101-ADO, its siRNA therapeutic for patients with Autosomal Dominant Osteopetrosis Type 2, has been granted Orphan Drug Designation by the U.S. FDA.

May 15, 2023
·
4 min read
Business

Rockwell Medical Announces First Quarter 2023 Results

Rockwell Medical, Inc., a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, announced financial and operational results for the three months ended March 31, 2023.

May 15, 2023
·
10 min read
Business

BiomX Reports First Quarter 2023 Financial Results and Provides Business Update

BiomX Inc., a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, reported financial results and provided a business update for the first quarter ended March 31, 2023.

May 15, 2023
·
11 min read
Genetown

Nido Biosciences Emerges as Clinical Stage Company Raising $109 Million to Advance Treatments for Debilitating Neurological Diseases

Nido Biosciences, a clinical stage company developing precision medicines for debilitating neurological diseases, emerged from stealth backed by an industry leading investor syndicate and having raised a combined $109 million in Seed, Series A and B financings.

May 15, 2023
·
4 min read
Business

Castellum, Inc. Announces First Quarter 2023 Financial Results and Provides Forward Guidance

Castellum, Inc. announces highlights of its operating results for its first quarter ended March 31, 2023, and provides expected revenue guidance for the 12-month period April 1, 2023 – March 31, 2024.

May 15, 2023
·
6 min read